Login to Your Account

Regeneron's ZALTRAP a Surprise Hit in Phase III

By Catherine Shaffer

Thursday, April 28, 2011
Regeneron Pharmaceuticals Inc.'s (Nasdaq:RGEN) stock surged 28 percent on news that its Phase III VELOUR trial of Zaltrap (aflibercept) for metastatic colon cancer hit its primary endpoint of improving overall survival. Regeneron and partner Sanofi-Aventis will waste no time preparing marketing approval applications for the FDA and European Medicines Agency for submission in the second half of 2011.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription